Core Insights - Silo Pharma has initiated its first Bitcoin purchase as part of a broader crypto reserve strategy aimed at multi-chain asset growth [1][2] - The CEO of Silo Pharma expressed confidence in Bitcoin as a store of value and a hedge against market volatility, highlighting the company's commitment to digital asset investments [2] - Silo Pharma's portfolio includes various therapeutic programs targeting conditions such as PTSD, fibromyalgia, and CNS diseases, indicating a diversified focus beyond cryptocurrency [3] Company Overview - Silo Pharma is a developmental-stage biopharmaceutical and cryptocurrency treasury company, focusing on underserved medical conditions [3] - The company collaborates with leading universities and laboratories for its research initiatives [3] Investment Strategy - The company has made multiple crypto investments, including Ethereum, RSC, and Solano tokens, and plans to continue expanding its digital asset portfolio [2] - The strategic approach reflects the company's belief in the growing adoption and value creation opportunities within the cryptocurrency market [2]

Core Insights - Silo Pharma Inc. has engaged Fireblocks as the custodian for its institutional crypto treasury platform, aiming to enhance security and governance standards [1][3] - Fireblocks has facilitated the secure transfer of over $6 trillion in digital assets, showcasing its capability in the digital asset space [2][3] - Silo Pharma's initial purchases of Ethereum (ETH) and Solana (SOL) tokens mark the beginning of its cryptocurrency treasury strategy, which was launched in August [5][6] Company Developments - The partnership with Fireblocks is expected to provide enterprise-grade security for Silo's crypto treasury platform [1][3] - Silo Pharma has appointed Corwin Yu as the first member of its Crypto Advisory Board to lead its cryptocurrency treasury strategy [5] - The company has also acquired AI-powered market intelligence technology to enhance decision-making capabilities [6] Market Context - The Fireblocks Network allows various financial entities, including exchanges and hedge funds, to securely scale their digital asset operations [4] - Silo Pharma's strategy aims to incorporate cryptocurrency into its treasury holdings and supports broader initiatives in blockchain and real-world asset tokenization [5]

Core Insights - Silo Pharma, Inc. announced the publication of preclinical research for its Alzheimer's disease therapeutic, SPC-14, in a leading scientific journal, Alzheimer's Research & Therapy [1][2] - The study indicates that the combination of (R,S)-ketamine and prucalopride is a novel therapeutic strategy for treating cognitive decline in Alzheimer's disease [2] - SPC-14 has shown promising results in improving cognitive decline in preclinical models, suggesting its potential as a therapeutic option for Alzheimer's disease [3] Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions, including Alzheimer's disease [5] - The company has developed SPC-14 under a sponsored research agreement with Columbia University and has an exclusive global license to further develop and commercialize the product [4] - Silo's portfolio includes other innovative programs targeting conditions such as PTSD and chronic pain, indicating a broad therapeutic focus [5] Market Potential - The Alzheimer's disease treatment market is projected to grow to $30.8 billion by 2033, with a compound annual growth rate (CAGR) of 18.8% [4][7] - SPC-14 targets glutamate receptor NMDAR and serotonin type 4 receptor 5HT4, addressing cognitive and neuropsychiatric symptoms associated with Alzheimer's disease [4]

Core Insights - Silo Pharma, Inc. announced positive bioanalytical and safety/toxicology results for its SPC-15 intranasal spray formulation, meeting FDA safety standards for clinical trials [1][2] - The study demonstrated that SPC-15's intranasal administration has comparable systemic exposure to oral administration while showing no identified toxicities, supporting its potential as a PTSD therapeutic [2][3] - The company is pursuing a 505(b)(2) regulatory strategy to streamline the FDA approval process by leveraging existing safety and efficacy data from approved drugs [3] Company Developments - Silo is conducting an IND-enabling GLP-compliant toxicology study and evaluating clinical CRO sites for first-in-human trials of SPC-15 [4] - The company focuses on addressing underserved conditions, including PTSD, chronic pain, and CNS diseases, with a portfolio that includes SPC-15 and other innovative programs [5] Market Insights - The PTSD market size was valued at $1.8 billion in 2024 and is projected to reach $3.2 billion by 2034, driven by increased focus on mental health and personalized treatment solutions [5]